Key-Docetaxel 20 mg, 80 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 14 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for various cancers including breast, lung, ovarian, prostate, and head and neck cancers.
Dosage (summary)
Administered as a one-hour infusion every three weeks; doses vary by cancer type.
Special Populations
- Elderly
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to teratogenic effects.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Ciclosporin
- Ketoconazole
- Erythromycin
Contraindications
- Severe hypersensitivity to docetaxel
- Baseline neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Hypersensitivity reactions
- Fluid retention
- Peripheral neuropathy
Counselling Points
- Monitor for hypersensitivity reactions
- Premedication with corticosteroids recommended
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Fluid retention
- Increased treatment-related mortality in liver impairment
Important Disclaimer
The Key-Docetaxel 20 mg, 80 mg Concentrate for solution for infusion professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
